WPI Related Analyst PT Change
-
Goldman Sachs Downgrades Watson Pharmaceuticals (WPI) to Neutral
-
Goldman Sachs Downgrades Watson Pharmaceuticals (WPI) to Buy
-
Leerink Swann Raises Valuation on Watson Pharmaceuticals (WPI); Getting That Out of The Way, Looking Ahead to More Challenges
-
Bernstein Upgrades Watson Pharmaceuticals (WPI) to Outperform
-
Piper Jaffray Downgrades Watson Pharmaceuticals (WPI) to Neutral
-
Wells Fargo Upgrades Watson Pharmaceuticals (WPI) to Outperform; Actavis Acquisition Adds Growth Prospects
-
Cantor Fitzgerald Maintains a 'Buy' on Warner Chilcott (WCRX); Let's Make It Official
-
UBS Maintains a 'Buy' on Watson Pharmaceuticals (WPI); Bullish on Acquisition Announcement
-
Canaccord Genuity Reiterates a 'Buy' on Watson Pharmaceuticals (WPI); Raising Numbers on Actavis Deal
Back to WPI Stock Lookup
